Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call
14 août 2023 17h06 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call
10 août 2023 20h31 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update
08 juin 2023 16h05 HE
|
Vivos Therapeutics, Inc
Revenue increased 6% Year-Over-Year; Operating Expenses Decreased 20% as Cost Cutting Initiatives Take Hold Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., June 08, 2023 ...
Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call
06 juin 2023 16h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Announces Additional Strategic Initiatives Aimed at Accelerating Anticipated Timeline for Cash Flow Positive Operations
09 mai 2023 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., May 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”, “the Company”) (NASDAQ:VVOS) today announced it has implemented a broad set of initiatives aimed at improving...
Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos’ POD® Appliance Treatment
01 mai 2023 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., May 01, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update
30 mars 2023 16h05 HE
|
Vivos Therapeutics, Inc
2022 and Early 2023 Accomplishments, Including Capital Raise, Cost Reductions and New Technology Acquisition, Set the Stage for Potential 2023 Revenue Growth Management to Host Conference Call...
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call
30 mars 2023 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETOWN, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical device and technology company that delivers training and a full...
Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference
08 mars 2023 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., March 08, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line...
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC
01 mars 2023 07h30 HE
|
Vivos Therapeutics, Inc
LITTLETON, Colo., March 01, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line...